Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2009
12/15/2009US7632866 Meclofenamic acid derivatives, for example; useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity
12/15/2009US7632865 N-(4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenyl)-2-chloro-5-nitrothiobenzamide, for example; useful as preventive or therapeutic medicines for diseases accompanied by hyperactivated immune functions
12/15/2009US7632864 Gabapentin analogues and process thereof
12/15/2009US7632862 (R)-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester as human Protein tyrosine phosphatases-beta (HPTP) inhibitor
12/15/2009US7632861 1-Isobenzofuranethanamine, 1-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-1,3-dihydro-N,N-dimethyl-; use in treating a disorder associated with aberrant levels of tachykinins or serotonin; nerve system disorders
12/15/2009US7632859 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
12/15/2009US7632858 For example, 1-(4-Cyano-2-ethyl-3-(trifluoromethyl)phenyl-1-carbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester; may be used in treatment of diseases or disorders associated with androgen receptor activity, such as maintenance of muscle strength and function in the elderly
12/15/2009US7632857 Histamine H3 receptor agents, preparation and therapeutic uses
12/15/2009US7632856 Indolone derivatives, processes for preparing them and their uses
12/15/2009US7632855 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers
12/15/2009US7632854 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/15/2009US7632853 Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
12/15/2009US7632852 (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics
12/15/2009US7632851 5-(2-Fluoro-ethylamino)-thiazol-2-yl-benzofurazan or 2,1,3-benzothiadiazole; fluorine radioactive or not; intensely and selectively stain amyloid deposits and vascular deposits of brain tissue; drug targets; diagnosis and treatment of Alzheimer's disease; fluorescent microscopy; tomography
12/15/2009US7632850 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS
12/15/2009US7632849 Indazolamides with analgesic activity
12/15/2009US7632848 Injection or infusion of bupivacaine to an eye muscle to enlarge and strengthen this muscle so as to put greater tension on the eye and pull it into an improvedalignment; strengthening a skeletal muscle that requires strengthening; dosage of0.25-5.0% concentration, volume of 1.0-7.0 ml
12/15/2009US7632847 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester
12/15/2009US7632846 Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
12/15/2009US7632845 Phenyl quinolines and their use as estrogenic agents
12/15/2009US7632844 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
12/15/2009US7632843 Administering LEK-8829 (9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8 beta-aminomethylergoline) as an antidote against acute (toxic) effects of cocaine overdosage to block euphorica effects, relieve the abstinence syndrome after withdrawal in addicts, and prevent craving for reinforcement
12/15/2009US7632841 Compositions use for increasing insulin sensitivity; formulations for minimizing the impurity associated with rosiglitazone maleate; safety and efficacy of product
12/15/2009US7632840 Quinazoline compounds for the treatment of hyperproliferative disorders
12/15/2009US7632839 Kinesin spindle protein (KSP) inhibitors, e.g., N-(3-amino-2-(R,S)-fluoropropyl)-N-[1-(3-benzyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-2-yl)-2-(R,S)-methylpropyl]-4-methylbenzamide; antiproliferative and -carcinogenic agents; side effects reduction
12/15/2009US7632838 11-beta HSD1 inhibitors
12/15/2009US7632837 6-(2-Chlorophenyl)-7-(4-chlorophenyl)-N-cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazin-3-amine; drug abuse, drug dependency; smoking cigarettes; appetite suppressants; antilipemic agents; anticholesterol agents; increasing high density lipoproteins;hypotensive agents; antidiabetic agents
12/15/2009US7632836 2-Morpholinoethyl ester of pivagabine; improved pharmacokinetic and therapeutic profiles; bioavailability; dosage; brain disorders; behavioral disorders; antidepressants; anxiolytic agents; neurodegenerative disorders; analgesics; eating disorders; antiarthritic agents; bipolar disorders; dysthymia
12/15/2009US7632835 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide; potent openers of the KCNQ family of potassium ion channels; antiepileptic agents; anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders
12/15/2009US7632834 Long acting beta-2-agonists and their use as medicaments
12/15/2009US7632833 Mitotic kinesin inhibitors
12/15/2009US7632832 Antagonist for calcitonin gene related peptide (Cgrp); azepinone ligands; migranes; headaches; 1-[(2-methoxyethyl)-2-oxo-6-phenylazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
12/15/2009US7632831 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
12/15/2009US7632830 Lactam compounds and pharmaceutical use thereof
12/15/2009US7632829 Diazepan derivatives
12/15/2009US7632828 1-Methyl, 2-((2-(2-(guanidinoethyl(dimethylammonium)ethyl-)(naphthyl-1,5-ylene)oxymethyl-),6-(1-hydroxyethyl-)carbapen-2-em-3-carboxylate; 1-methylcarbapenems as bactericides; drug resistance; multidrug resistance; methicillin-resistant Staphylococcus aureus (MRSA) and S. epidermidis(MRSE)
12/15/2009US7632827 Anti-cancer phosphine containing [AuIIIm(CNC)mL]n+ complexes and derivatives thereof and methods for treating cancer using such compositions
12/15/2009US7632826 Use of agonists of the glucocorticosteroid and/or mineralo-corticosteroid receptors, in particular corticosteroids for the treatment of addiction
12/15/2009US7632825 Methods of decreasing or preventing pain using spicamycin derivatives
12/15/2009US7632824 Nucleobase sequence of a modified oligonucleotide complementary to a nucleic acid molecule encoding human Mcl-1, an antipoptoic protein of the Bcl-2 family; targeting and modulating expression of Mcl-1 in cells, tissue; antisense therapy, antitumor, -carcinogenic and -proliferative agents; autoimmune
12/15/2009US7632822 For prophylaxis and therapy of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen
12/15/2009US7632821 2'-C-(methyl-),2'-O-,3'-O-(benzylidene)<)adenosine; hepatitus C virus prodrugs ofpolymerase enzyme inhibitors; inhibition of HCV NS5B polymerase prevents formation ofthe double-stranded Hepitis C virus RNA; replication-defecctive; viral infections; Flaviviruses; picornavirus; rhinovirus; polio virus
12/15/2009US7632820 4'-desoxy-4'-(phenylamino-carbonyl-hydrazono)-avermectin B1 monosaccharide; biocidal, very broad spectrum at low concentrations; endo-/ectopararsiticides in humans; insecticides; nematocides; miticides; agriculture; crops; veterinary medicine
12/15/2009US7632815 Treating or preventing myocardial contractile dysfunction that occurs after a myocardial infarction or other structural heart disease (e.g., end-stage valve disease) by by administering CaMK11 inhibitor, a peptide having a specific sequence of amino acids; dilated cardiomyopathy; transgenic animals
12/15/2009US7632813 Administering N-(3-{2-[3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxamideas an inhibitor and a type of parathyroid hormone to treat and/orprevent bone metabolic diseases
12/15/2009US7632808 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
12/15/2009US7632782 Synergistically acting herbicidal mixtures
12/15/2009US7632643 PCA3, PCA3 genes, and methods of use
12/15/2009US7632527 Compositions for juice-based peels and masks
12/15/2009US7632525 Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
12/15/2009US7632520 Contains Cefixime Trihydrate, Cloxacillin Sodium (sustained release and immediate release form), Lactobacillus sporogenes spores
12/15/2009US7632518 Microencapsulated oil
12/15/2009US7632517 Buccal, polar and non-polar spray containing zolpidem
12/15/2009US7632510 Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence
12/15/2009US7632490 Use of IL-1 antagonists to treat gout
12/15/2009CA2607940C Bir domain binding compounds
12/15/2009CA2601208C Method of preventing or treating type 1 diabetes by gene therapy with a secreted form of glutamic acid decarboxylase.
12/15/2009CA2555454C Mycophenolate mofetil impurity
12/15/2009CA2550459C Tellurium derivatives for prevention and treatment of neurodegenerative processes
12/15/2009CA2537400C .gamma. crystalline form of ivabradine chlorhydrate, process for the preparation thereof and pharmaceutical compounds containing it
12/15/2009CA2529611C Pyrimidine derivatives for the treatment of abnormal cell growth
12/15/2009CA2525854C Acylsulfamide inhibitors of factor viia
12/15/2009CA2502264C N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials
12/15/2009CA2501820C Chitosan-containing polysaccharide, method for preparing the same and use thereof
12/15/2009CA2481459C A pharmaceutical composition for treating rheumatism and the preparation thereof
12/15/2009CA2481078C Method and compositions for the synthesis of bch-189 and related compounds
12/15/2009CA2476496C Controlled release dosage forms
12/15/2009CA2469684C Pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
12/15/2009CA2424884C Substituted (e)-styryl benzylsulfones for treating proliferative disorders
12/15/2009CA2422698C Indoline derivatives and their use as 5-ht2 receptor ligands
12/15/2009CA2419302C Use of 2-iminobiotin for the prevention or treatment of perinatal asphyxia in neonates
12/15/2009CA2408796C Method of stabilizing preparation
12/15/2009CA2405747C Aminoflavone compounds, compositions, and methods of use thereof
12/15/2009CA2403110C N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
12/15/2009CA2399087C Use of retinoid-type compounds as antibacterial agents
12/15/2009CA2398908C Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
12/15/2009CA2393437C Exo-s-mecamylamine formulation and use in treatment
12/15/2009CA2388915C Process for the preparation of n-(4,5-bismethanesulfonyl-2-methyl-benzoyl)guanidine, hydrochloride
12/15/2009CA2388320C N-substituted carbamoyloxyalkyl-azolium derivatives
12/15/2009CA2386782C Bioadhesive nanoparticulate compositions having cationic surface stabilizers
12/15/2009CA2386379C Carbonyl stress-decreasing agent
12/15/2009CA2373180C Propanoic acid derivatives that inhibit the binding of integrins to their receptors
12/15/2009CA2348445C Compositions for the treatment and prevention of cardiovascular diseases
12/15/2009CA2347905C P53 antisense agent and method
12/15/2009CA2345295C Use of fused pyrrolocarbazoles in preventing/treating damage to sensory hair cells and cochlear neurons
12/15/2009CA2343471C Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy
12/15/2009CA2339008C Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
12/15/2009CA2338000C Water-soluble 4-thio-maleimido derivatives and methods for their production
12/15/2009CA2335617C Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
12/15/2009CA2334189C Bridged indenopyrrolocarbazoles
12/15/2009CA2330545C Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
12/15/2009CA2316349C Compositions and method for protecting skin from uv induced immunosuppression and skin damage
12/15/2009CA2312164C Antioxidant activity in sdg metabolites
12/15/2009CA2295195C Compositions and methods for preventing restenosis following revascularization procedures
12/15/2009CA2294996C Angiotensin derivatives
12/15/2009CA2276306C Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer
12/15/2009CA2267175C Alpha-9 integrin antagonists and anti-inflammatory compositions thereof
12/15/2009CA2259185C High dose liposomal aerosol formulations
12/15/2009CA2255614C Dha-pharmaceutical agent conjugates
12/15/2009CA2248960C Stable factor viii/vwf-complex